{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:41:51Z","timestamp":1759693311158,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["MSM0021622404"],"award-info":[{"award-number":["MSM0021622404"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.mehy.2012.04.041","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T13:33:50Z","timestamp":1337261630000},"page":"216-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Could piracetam potentiate behavioural effects of psychostimulants?"],"prefix":"10.1016","volume":"79","author":[{"given":"Karel","family":"Slais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Machalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leos","family":"Landa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Vrskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Sulcova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2012.04.041_b0005","first-page":"115","article-title":"Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology","volume":"25","author":"Giurgea","year":"1972","journal-title":"Actual Pharmacol (Paris)"},{"issue":"6","key":"10.1016\/j.mehy.2012.04.041_b0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/00023210-199809060-00006","article-title":"Piracetam \u2013 a review of its clinical potential in the management of patients with stroke","volume":"9","author":"Noble","year":"1998","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.mehy.2012.04.041_b0015","first-page":"229","article-title":"Interaction between nootropic drugs and methamphetamine on avoidance acquisition but not on locomotor activity in mice","volume":"278","author":"Sansone","year":"1985","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.mehy.2012.04.041_b0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0404.1986.tb04871.x","article-title":"Piracetam potentiates the antiepileptic action of carbamazepine in chronic experimental limbic epilepsy","volume":"109","author":"Hawkins","year":"1986","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.mehy.2012.04.041_b0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0404.1986.tb04870.x","article-title":"Synergistic effects of oxiracetam and piracetam in combination with antiepileptic drugs","volume":"109","author":"Mondadori","year":"1986","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.mehy.2012.04.041_b0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1600-0404.1984.tb05679.x","article-title":"Potentiation of the anticonvulsant effects of antiepileptic drugs by \u201cnootropics\u201d; a potential new therapeutic approach","volume":"99","author":"Mondadori","year":"1984","journal-title":"Acta Neurol Scand Suppl"},{"issue":"4","key":"10.1016\/j.mehy.2012.04.041_b0035","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/BF00427572","article-title":"Facilitation of diazepam action by anticonvulsant agents against picrotoxin induced convulsions","volume":"81","author":"Kulkarni","year":"1983","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.mehy.2012.04.041_b0040","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","article-title":"Mechanisms of neurotransmitter release by amphetamines: a review","volume":"75","author":"Sulzer","year":"2005","journal-title":"Prog Neurobiol"},{"issue":"2","key":"10.1016\/j.mehy.2012.04.041_b0045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/0165-0173(94)90011-6","article-title":"Piracetam and other structurally related nootropics","volume":"19","author":"Gouliaev","year":"1994","journal-title":"Brain Res Brain Res Rev"},{"issue":"2","key":"10.1016\/j.mehy.2012.04.041_b0050","first-page":"6","article-title":"The effect of a low dose of piracetam on the activity of the dopaminergic system in the rat striatum","volume":"59","author":"Budygin","year":"1996","journal-title":"Eksp Klin Farmakol"},{"issue":"4","key":"10.1016\/j.mehy.2012.04.041_b0055","first-page":"6","article-title":"Changes in the brain biogenic monoamines of rats, induced by piracetam and aniracetam","volume":"10","author":"Petkov","year":"1984","journal-title":"Acta Physiol Pharmacol Bulg"},{"issue":"1","key":"10.1016\/j.mehy.2012.04.041_b0060","first-page":"62","article-title":"Effects of nootropic drugs on brain cholinergic and dopaminergic transmission","volume":"29","author":"Pavlik","year":"1987","journal-title":"Act Nerv Super (Praha)"},{"issue":"3","key":"10.1016\/j.mehy.2012.04.041_b0065","first-page":"261","article-title":"Effect of piracetam, a nootropic agent, on rat brain monoamines and prostaglandins","volume":"27","author":"Bhattacharya","year":"1989","journal-title":"Indian J Exp Biol"},{"issue":"1","key":"10.1016\/j.mehy.2012.04.041_b0070","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bcp.2007.06.039","article-title":"Glutamatergic substrates of drug addiction and alcoholism","volume":"75","author":"Gass","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2012.04.041_b0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neubiorev.2010.02.001","article-title":"Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory","volume":"35","author":"Ikemoto","year":"2010","journal-title":"Neurosci Biobehav Rev"},{"issue":"9","key":"10.1016\/j.mehy.2012.04.041_b0080","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1023\/A:1020769816332","article-title":"Amphetamine increases extracellular concentrations of glutamate in the prefrontal cortex of the awake rat: a microdialysis study","volume":"23","author":"Del Arco","year":"1998","journal-title":"Neurochem Res"},{"issue":"1","key":"10.1016\/j.mehy.2012.04.041_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0047-6374(00)00225-6","article-title":"Glutamatergic neurotransmission in aging: a critical perspective","volume":"122","author":"Segovia","year":"2001","journal-title":"Mech Ageing Dev"},{"issue":"5","key":"10.1016\/j.mehy.2012.04.041_b0090","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jmri.22366","article-title":"Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder","volume":"32","author":"Ernst","year":"2010","journal-title":"J Magn Reson Imaging"},{"issue":"5","key":"10.1016\/j.mehy.2012.04.041_b0095","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1021\/jm901905j","article-title":"Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors","volume":"53","author":"Ahmed","year":"2010","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.mehy.2012.04.041_b0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuron.2010.06.004","article-title":"AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future","volume":"67","author":"Bowers","year":"2010","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.mehy.2012.04.041_b0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neuroscience.2007.09.044","article-title":"Methamphetamine induces alterations on hippocampal NMDA and AMPA receptor subunit levels and impairs spatial working memory","volume":"150","author":"Simoes","year":"2007","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.mehy.2012.04.041_b0110","first-page":"405","article-title":"Piracetam \u2013 an old drug with novel properties?","volume":"62","author":"Winnicka","year":"2005","journal-title":"Acta Pol Pharm"},{"issue":"25\u201326","key":"10.1016\/j.mehy.2012.04.041_b0115","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/0024-3205(94)00398-X","article-title":"In search of the mechanism of action of the nootropics: new insights and potential clinical implications","volume":"55","author":"Mondadori","year":"1994","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.mehy.2012.04.041_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00002512-199101010-00004","article-title":"Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders","volume":"1","author":"Vernon","year":"1991","journal-title":"Drugs Aging"},{"issue":"8","key":"10.1016\/j.mehy.2012.04.041_b0125","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0006-2952(95)00225-O","article-title":"Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis","volume":"50","author":"Peuvot","year":"1995","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2012.04.041_b0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-2952(96)00463-7","article-title":"Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain","volume":"53","author":"Muller","year":"1997","journal-title":"Biochem Pharmacol"},{"issue":"7\u20138","key":"10.1016\/j.mehy.2012.04.041_b0135","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s007020050196","article-title":"Piracetam reverses hippocampal membrane alterations in Alzheimer\u2019s disease","volume":"106","author":"Eckert","year":"1999","journal-title":"J Neural Transm"},{"issue":"1","key":"10.1016\/j.mehy.2012.04.041_b0140","first-page":"47","article-title":"Piracetam attenuates the changes in the surface potential of the phosphatidylcholine monolayer produced by alcohols","volume":"36","author":"Fassoulaki","year":"1985","journal-title":"Acta Anaesthesiol Belg"},{"issue":"2","key":"10.1016\/j.mehy.2012.04.041_b0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1527-3458.2005.tb00268.x","article-title":"Piracetam: a review of pharmacological properties and clinical uses","volume":"11","author":"Winblad","year":"2005","journal-title":"CNS Drug Rev"},{"issue":"Suppl 1","key":"10.1016\/j.mehy.2012.04.041_b0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1055\/s-2007-979230","article-title":"Piracetam: novelty in a unique mode of action","volume":"32","author":"Muller","year":"1999","journal-title":"Pharmacopsychiatry"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030698771200206X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030698771200206X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:13:18Z","timestamp":1759691598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030698771200206X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S030698771200206X"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2012.04.041","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could piracetam potentiate behavioural effects of psychostimulants?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2012.04.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}